GlassScriptPhysician profile
Alan Josselson
NPI 1053373464
$9,014.90
in general payments reported to CMS, 2019-2025
33 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,635 · 2020: $2,320 · 2021: $1,154 · 2022: $605 · 2023: $913 · 2024: $805 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,314.85 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,891.08 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.71 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $535.18 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $434.25 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $357.73 | 2019 | |
| Mallinckrodt Hospital Products INC. | $354.44 | 2020-2021 | |
| Insmed, INC. | $299.52 | 2019-2021 | |
| United Therapeutics Corporation | $286.21 | 2019-2023 | Tyvaso |
| Mylan Specialty L.P. | $247.67 | 2019-2021 | |
| Philips North America LLC | $216.43 | 2019-2020 | |
| Inspire Medical Systems, INC. | $191.21 | 2019-2025 | Inspire |
| Grifols USA, LLC | $130.84 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.44 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $113.42 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $102.13 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $87.05 | 2019-2020 | |
| Genentech USA, INC. | $78.30 | 2019-2020 | |
| Genzyme Corporation | $77.22 | 2022 | |
| Circassia INC. | $68.11 | 2019 | |
| Electromed, INC. | $67.00 | 2019-2025 | Smartvest |
| Resmed Corp | $49.59 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $49.42 | 2019 | |
| Harmony Biosciences LLC | $47.62 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $33.12 | 2019-2020 | |
| Ibsa Pharma INC. | $23.70 | 2025 | Licart, Flector, Tirosint |
| Biogen, INC. | $22.61 | 2025 | Skyclarys |
| Janssen Pharmaceuticals, INC | $18.30 | 2020 | |
| Eisai INC. | $18.21 | 2021 | |
| Acella Pharmaceuticals, LLC | $16.93 | 2025 | NP Thyroid 60 |
| E.R. Squibb & Sons, L.L.C. | $16.19 | 2019 | |
| Pfizer INC. | $15.45 | 2019 | |
| Horizon Therapeutics Plc | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Josselson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.